---
edited: 2024-03-02
tags:
---
### Pathophysiology
- Seen in patients with diabetes for > 10 years
- Chronic hyperglycemia → non-enzymatic glycosylation (NEG) of the basement membrane (protein glycation) → increased permeability and thickening of the basement membrane and stiffening of the efferent arteriole → hyperfiltration (increase in GFR) → increase in intraglomerular pressure   → progressive glomerular hypertrophy, increase in renal size, and glomerular scarring (glomerulosclerosis) → worsening of filtration capacity
- **Pathology**: 
- Three major histological changes can be seen on LM. (Chronic hyperglycemia, hyperlipidemia, elevated levels of growth hormones, and intraglomerular hypertension are responsible for these changes.)
	- Mesangial expansion
	- Glomerular basement membrane thickening
	- Glomerulosclerosis (later stages)
	- Diffuse hyalinization (most common) or
- Pathognomonic nodular glomerulosclerosis (Kimmelstiel-Wilson nodules)   
- Glomerular capillary hypertension and hyperfiltration → increase in mesangial matrix → eosinophilic hyaline material in the area of glomerular capillary loops
- Can progressively consume the entire glomerulus → hypofiltration (↓ GFR) [49]

### Clinical features
- Often asymptomatic; patients may complain of foamy urine
- Progressive diabetic kidney disease with signs of renal failure and risk of uremia (e.g., [[uremic polyneuropathy]])
- Arterial hypertension
- Features of [[CKD]] 
### Diagnostics
- Urine analysis: proteinuria
- Initially moderately increased albuminuria (**microalbuminuria**)
- Eventually significantly increased albuminuria (macroproteinuria): nephrotic syndrome may develop.
- Differential diagnoses: other causes of chronic kidney disease (e.g., hypertensive nephropathy) and nephrotic syndrome

### Prevention and management
- Stringent glycemic control 
- Antihypertensive treatment: ACE inhibitors OR angiotensin-receptor blockers are the first-line antihypertensive drugs in patients with diabetes.  
- Second line agents to be added to ACE inhibitors or ARBs to further control hypertension include diuretics or calcium channel blockers
- Dietary modification: daily salt intake < 5–6 g/day; phosphorus and potassium intake restriction in advanced nephropathy; protein restriction 
### Screening
- Microalbuminuria is the earliest clinical sign of diabetic nephropathy. The extent of albuminuria correlates with the risk of cardiovascular disease!
 - screening for proteinuria in patients with type 2 diabetes is recommended at initial diagnosis, then at least once a year. 
 - Screening in patients with type 1 diabetes is also recommended yearly, beginning 5 years after disease onset. 
 - Diabetic nephropathy usually develops after 5 years with diabetes mellitus; however, patients with type 2 diabetes may present with renal damage at diagnosis. 
 - Many patients with type 2 diabetes have additional risk factors for kidney disease (e.g., hypertension).)
- Early antihypertensive treatment delays the progression of diabetic nephropathy!

---




- [[Hyporeninemic hypoaldosteronism]] 